OakChart

Disc Medicine Inc

IRONHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

87.08+2.44 (2.88%)
2026-11-12 01:00 CET
Market cap
3,249.57 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-243.10 USD m
Free cash flow, TTM
-189.96 USD m
EPS diluted, TTM
-6.34
P/E
-
Compare

Price

IRON against its 20, 50 and 200-day averages
2050200beat
60.0070.0080.004.2M8.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IRONclose 87.0820-day 77.7750-day 71.52200-day 70.9387.08

12.5% under the 52-week high of 99.50 on 8 Dec 2025. 52-week low 40.00 on 13 Feb 2026. Last 15 sessions, 18.2% high to low

Volume 0.75× normal · the line is the 50-bar volume average

Profile

IRON
52-week range, 79% of the way up
40.0099.50

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

IndexRUT
Employees155
IPOAug 12, 2020
Beta0.91
ATR, 14d4.12
Rel volume0.75
Short float24.38%
Insider own26.67%
Inst own97.56%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.97B
Enterprise Value3.34B
Income-243.10M
Sales0.00M
Book/sh15.65
Cash/sh14.99
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees155
IPOAug 12, 2020

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.57
P/C5.81
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio20.30
Current Ratio20.30
Debt/Eq0.10
LT Debt/Eq0.10
Option/ShortYes / Yes

Earnings

EPS (ttm)-6.34
EPS next Y-5.98
EPS next Q-1.48
EPS this Y1.59%
EPS next Y-1.11%
EPS next 5Y9.28%
EPS past 3/5Y48.90% 25.96%
Sales past 3/5Y- -
EPS Y/Y TTM-18.27%
Sales Y/Y TTM-
EPS Q/Q13.62%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.6.32% -

Ownership

Insider Own26.67%
Insider Trans-2.24%
Inst Own97.56%
Inst Trans3.34%
ROA-36.56%
ROE-41.29%
ROIC-36.55%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2011.98%
SMA5021.76%
SMA20022.78%
Trades-

Technical

Shs Outstand38.62M
Shs Float28.15M
Short Float24.38%
Short Ratio7.66
Short Interest6.86M
52W High99.50 -12.48%
52W Low40.00 117.70%
Volatility5.52% 5.57%
ATR (14)4.12
RSI (14)66.93
Beta0.91
Rel Volume0.75
Avg Volume895.55K
Volume669,059

Performance

Perf Week4.56%
Perf Month53.85%
Perf Quarter8.84%
Perf Half Y24.35%
Perf YTD9.66%
Perf Year1.17%
Perf 3Y79.29%
Perf 5Y156.12%
Perf 10Y-
Recom1.00
Target Price126.77
Prev Close84.64
Price87.08
Change %2.88%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 09, 2026InitiatedGGuggenheimBuy$132+51.6%
Nov 03, 2025ResumedSStifelBuy$125+43.5%
Jul 21, 2025InitiatedTTruistBuy$86-1.2%
Jul 03, 2025ResumedMMorgan StanleyOverweight$85-2.4%
Jun 11, 2025ResumedRRaymond JamesStrong Buy$89+2.2%
Feb 27, 2025InitiatedTTD CowenBuy
Nov 05, 2024UpgradeMMorgan StanleyEqual-Weight → Overweight$85-2.4%
Nov 04, 2024UpgradeRRaymond JamesOutperform → Strong Buy$66 → $110+26.3%
Oct 23, 2024InitiatedJJefferiesBuy$89+2.2%
Oct 16, 2024InitiatedBScotiabankSector Outperform

Peers

Mkt cap
TickerCompanyMkt cap
PTGXProtagonist Therapeutics Inc8.80B
AGIOAgios Pharmaceuticals Inc1.96B
SLNSilence Therapeutics Plc ADR1.23B
IONSIonis Pharmaceuticals Inc4.72B
GERNGeron Corp657.13M
DMRADamora Therapeutics Inc1.44B
INCYIncyte Corp24.92B
RIGLRigel Pharmaceuticals838.31M
FULCFulcrum Therapeutics Inc285.36M
KROSKeros Therapeutics Inc187.22M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
WILLIAM SAVAGEOfficerNov 10 '26Proposed Sale81.2616,0351,303,004Nov 10 04:23 PM
Bitterman KevinDirectorOct 21 '26Sale80.2325,5192,047,38912,991Oct 21 05:33 PM
Bitterman KevinDirectorOct 19 '26Sale79.9710,994879,19013,312Oct 21 05:33 PM
Bitterman KevinDirectorOct 20 '26Sale79.955,312424,69413,257Oct 21 05:33 PM
Atlas Venture Opportunity FundShareholderOct 21 '26Proposed Sale79.4811,470911,636Oct 21 05:12 PM
Atlas Venture Opportunity FundShareholderOct 21 '26Proposed Sale79.4813,7831,095,473Oct 21 05:11 PM
Atlas Venture Fund X, LPShareholderOct 21 '26Proposed Sale79.4833,4612,659,480Oct 21 05:11 PM
Atlas Venture Fund XII, LPShareholderOct 21 '26Proposed Sale79.4826621,142Oct 21 05:11 PM
Atlas Venture Opportunity FundShareholderOct 20 '26Proposed Sale78.932,388188,485Oct 20 05:16 PM
Atlas Venture Opportunity FundShareholderOct 20 '26Proposed Sale78.932,869226,450Oct 20 05:16 PM
Atlas Venture Fund X, LPShareholderOct 20 '26Proposed Sale78.936,965549,747Oct 20 05:15 PM
Atlas Venture Fund XII, LPShareholderOct 20 '26Proposed Sale78.93554,341Oct 20 05:15 PM
Atlas Venture Opportunity FundShareholderOct 19 '26Proposed Sale56.844,942280,903Oct 19 04:44 PM
Atlas Venture Opportunity FundShareholderOct 19 '26Proposed Sale56.845,937337,459Oct 19 04:44 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VXFVanguard Extended Market Index ETFAUM: 30.47B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
JGROJPMorgan Active Growth ETFAUM: 9.31B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-1.530-1.633-1.5300.000.0012
2026Q22026-07-30-1.540-1.713-1.5390.000.0012
2026Q12026-05-05-1.650-1.646-1.6500.000.4411
2025Q42026-02-26-1.640-1.710-1.6180.000.0013
2025Q32025-11-06-1.770-1.442-1.7720.000.0013
2025Q22025-08-07-1.580-1.128-1.5770.000.0013
2025Q12025-05-07-1.020-1.107-1.0230.000.0010
2024Q42025-02-27-0.950-1.096-0.9860.000.0011
2024Q32024-11-12-0.890-1.037-0.8890.000.0012
2024Q22024-08-08-1.030-1.104-1.0270.000.009
2024Q12024-05-09-1.090-1.008-1.0860.000.008
2023Q42024-03-21-0.900-0.771-0.9680.000.008
2023Q32023-11-09-0.580-0.800-0.5810.000.009
2023Q22023-08-11-0.740-0.863-0.7420.000.009
2023Q12023-05-15-1.200-0.667-1.2020.000.007
2022Q42023-03-31-0.760-0.805-1.2200.000.002

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-68.900-73.000-27.0170.000.00
2021FY-17.800-18.025-40.9480.000.00
2022FY-45.050-5.150-45.0480.000.00
2023FY-3.420-3.251-3.4250.000.00
2024FY-3.960-4.115-3.9610.000.00
2025FY-6.010-5.996-6.0100.000.00
2026FY--5.915--0.00
2027FY--5.980--43.24
2028FY--4.488--165.86
2029FY--1.205--400.02
2030FY-3.670--683.28

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-069000.000.000.00
2026Q4S2026-11-058000.000.000.00
2026Q4S2026-07-307000.000.000.00
2026Q4S2026-07-197000.000.000.00
2026Q4S2026-05-127110.000.000.00
2026Q4S2026-05-087120.000.000.00
2026Q4S2026-05-058123.700.0029.60
2026Q4S2026-04-298016.64-4.5029.60
2026Q4S2026-04-288036.64-4.5029.60
2026Q4S2026-04-138066.64-4.5029.60
2026Q4S2026-03-228166.64-4.5029.60
2026Q4S2026-02-269167.90-4.5029.60
2026Q4S2026-02-2592510.19-4.5029.60
2026Q4S2026-02-1392610.19-4.5029.60

Estimate history

EPS, annual-27.017-40.948-45.048-3.425-3.961-6.012-6.3369
Period202020212022202320242025TTM
EPS, quarterly-0.889-0.986-1.023-1.577-1.772-1.618-1.65-1.539-1.53
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.5570.90917.40324.3629.86537.89138.619
Period202020212022202320242025MRQ
Shares, quarterly29.74829.86534.58134.69535.00737.89138.1938.34638.619
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.360.280.160.100.300.190.32
Gross Profit-0.36-0.28-0.16-0.10-0.30-0.19-0.32
Selling, General and Administrative Excl. Other265.37235.74129.5691.0347.1730.7433.72
Research and Development182.78170.3696.5269.1633.3525.1427.85
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-265.73-236.02-129.72-91.12-47.48-30.93-34.04
Interest Expense4.353.610.570.00-2.166.83
Unusual Expense0.000.000.001.500.065.050.01
Net Income Before Taxes-242.78-211.82-109.00-76.33-46.83-35.97-40.84
Income Taxes0.320.360.350.100.000.000.00
Consolidated Net Income-243.10-212.18-109.36-76.43-46.83-35.97-40.84
Net Income From Continuing Operations-243.10-212.18-109.36-76.43-46.83-35.97-40.84
Net Income-243.10-212.18-109.36-76.43-46.83-35.97-40.84
EPS (Recurring)-6.25-6.01-3.96-3.38-45.01-36.92-27.01
EPS (Basic, Before Extraordinaries)-6.34-6.01-3.96-3.42-45.05-40.95-27.02
EPS (Diluted)-6.34-6.01-3.96-3.42-45.05-40.95-27.02
EBITDA-265.37-235.74-129.56-91.03-47.17-30.74-33.72
Non-Operating Income (Expense)27.2927.8121.2916.300.710.010.04
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense39.9327.1313.284.372.090.510.98
Shares Outstanding38.6237.8929.8724.3617.400.911.56
Market Capitalization3,249.573,249.571,886.641,394.3586.12125.74170.89

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.090.090.090.090.090.090.020.01
Gross Profit-0.09-0.09-0.09-0.09-0.09-0.09-0.02-0.01
Selling, General and Administrative Excl. Other64.0764.9869.4466.8867.6161.3339.9334.54
Research and Development43.9946.8445.8146.1350.2546.2327.7424.79
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-64.16-65.08-69.52-66.97-67.70-61.41-39.95-34.55
Interest Expense1.710.910.840.880.920.910.900.57
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-59.43-59.46-63.45-60.44-62.22-55.20-33.97-29.28
Income Taxes0.110.070.050.090.100.050.120.18
Consolidated Net Income-59.53-59.53-63.50-60.53-62.32-55.25-34.09-29.46
Net Income From Continuing Operations-59.53-59.53-63.50-60.53-62.32-55.25-34.09-29.46
Net Income-59.53-59.53-63.50-60.53-62.32-55.25-34.09-29.46
EPS (Recurring)-1.53-1.54-1.65-1.62-1.77-1.58-1.02-0.99
EPS (Basic, Before Extraordinaries)-1.53-1.54-1.65-1.62-1.77-1.58-1.02-0.99
EPS (Diluted)-1.53-1.54-1.65-1.62-1.77-1.58-1.02-0.99
EBITDA-64.07-64.98-69.44-66.88-67.61-61.33-39.93-34.54
Non-Operating Income (Expense)6.456.526.927.416.397.126.885.84
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.5411.029.447.937.526.655.033.42
Shares Outstanding38.6238.3538.1937.8935.0134.6934.5829.87
Market Capitalization3,249.572,793.882,439.962,997.742,297.311,834.231,716.011,886.64

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments791.15489.88360.38194.7988.214.50
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets12.753.735.283.702.270.56
Total Current Assets803.90493.62365.66198.4990.485.07
Net Property, Plant & Equipment2.252.322.101.601.750.29
Total Investments and Advances0.000.840.230.000.000.32
Intangible Assets-0.000.00--0.00
Other Assets0.730.000.000.120.182.64
Total Assets806.88496.77368.00200.2192.418.32
Short Term Debt Incl. Current Port. of LT Debt0.610.130.670.310.3216.69
Accounts Payable9.027.9512.6316.162.562.38
Other Current Liabilities27.0115.248.146.1110.555.81
Total Current Liabilities36.6423.3221.4422.5813.4224.88
Long Term Debt30.4129.871.441.031.334.95
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.35
Total Liabilities67.0553.1922.8823.6114.7630.18
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00141.860.00
Common Equity739.83443.59345.12176.60-64.20-21.86
Total Shareholders Equity739.83443.59345.12176.6077.65-21.86
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity739.83443.59345.12176.6077.65-21.86
Total Liabilities & Stockholders Equity806.88496.77368.00200.2192.418.32
Book Value Per Share19.5314.8514.1710.15-70.60-14.04
Tangible Book Value Per Share19.5314.8514.1710.15-70.60-14.04
Full-Time Employees155847446333
Price to Book Ratio5.414.033.880.821.011.46
Return on Assets-32.55-25.29-26.90-27.49-71.42-
Return on Equity-35.86-27.73-29.30-31.07-128.94-
Return on Invested Capital-27.55-23.10-22.05-26.36-45.54-
Quick Ratio21.9421.1717.068.796.740.20
Current Ratio21.9421.1717.068.796.740.20

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-243.10-212.18-109.36-76.43-46.83-35.97-40.84
Depreciation0.360.280.160.100.300.190.32
Other Funds (Non Cash)48.6527.9812.045.822.156.967.47
Funds from Operations-194.09-183.92-97.16-70.51-44.38-28.82-33.05
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital4.163.533.23-2.952.121.290.34
Cash from Operating Activities-189.94-180.39-93.93-73.46-42.25-27.53-32.71
Capital Expenditures-0.02-0.93-0.51-0.09-0.15-0.07-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments-117.61-393.37-291.830.000.000.000.00
Purchase of Investments-663.25-849.59-386.630.000.000.000.00
Sale Or Maturity of Investments545.64456.2294.800.000.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-117.63-394.30-292.33-0.09-0.15-0.07-0.02
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock225.23472.83190.28239.3853.7289.9320.25
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock225.23472.83190.28239.3853.7289.9320.25
Proceedsfrom Stock Options206.34450.11187.30199.0853.5089.8620.08
Issuance or Reduction of Debt, Net29.980.0027.590.000.000.0014.00
Change in Long Term Debt29.980.0027.590.000.000.000.00
Issuance of Long Term Debt29.980.0027.590.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow1.670.580.440.0095.260.000.00
Other Financing Activities Uses0.000.000.000.00-2.140.000.00
Cash from Financing Activities256.89473.41218.31239.38148.9889.9334.25
Net Change in Cash-50.68-101.28-167.94165.83106.5862.331.52
Free Cash Flow-189.96-181.33-94.43-73.55-42.40-27.60-32.73
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments682.82717.75730.16791.15615.92649.97
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets14.5915.0217.3012.7511.2511.62
Total Current Assets697.40732.76747.46803.90627.17661.59
Net Property, Plant & Equipment1.591.812.042.252.452.63
Total Investments and Advances0.000.000.000.000.240.24
Intangible Assets----0.000.00
Other Assets0.500.500.720.730.600.60
Total Assets699.49735.07750.21806.88630.46665.06
Short Term Debt Incl. Current Port. of LT Debt0.210.320.420.610.660.63
Accounts Payable6.076.8411.769.027.276.35
Other Current Liabilities28.0823.2018.9627.0118.8213.62
Total Current Liabilities34.3630.3631.1436.6426.7420.61
Long Term Debt60.8860.5530.6430.4130.3230.29
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities95.2490.9161.7867.0557.0650.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity604.25644.16688.43739.83573.39614.16
Total Shareholders Equity604.25644.16688.43739.83573.39614.16
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity604.25644.16688.43739.83573.39614.16
Total Liabilities & Stockholders Equity699.49735.07750.21806.88630.46665.06
Book Value Per Share15.6516.8018.0319.5316.3817.70
Tangible Book Value Per Share15.6516.8018.0319.5316.3817.70
Full-Time Employees173-154155--
Price to Book Ratio5.414.063.274.853.732.77
Return on Assets-36.56-35.12-33.11-32.55-32.18-24.74
Return on Equity-41.29-39.08-35.83-35.86-34.78-26.36
Return on Invested Capital-8.95-8.45-8.83-7.86-10.32-8.57
Quick Ratio20.3024.1424.0021.9423.4532.11
Current Ratio20.3024.1424.0021.9423.4532.11

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-59.53-59.53-63.50-60.53-62.32-55.25
Depreciation0.090.090.090.090.090.09
Other Funds (Non Cash)14.8913.8111.208.758.116.96
Funds from Operations-44.55-45.63-52.22-51.70-54.13-48.20
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.351.43-10.028.396.330.28
Cash from Operating Activities-40.20-44.20-62.24-43.30-47.80-47.92
Capital Expenditures0.000.000.00-0.02-0.03-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments25.3321.6358.31-222.8749.5651.73
Purchase of Investments-118.48-92.73-93.76-358.27-85.44-58.63
Sale Or Maturity of Investments143.81114.36152.07135.40135.00110.35
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities25.3321.6358.31-222.8949.5451.69
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock5.772.361.01216.1011.590.89
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock5.772.361.01216.1011.590.89
Proceedsfrom Stock Options0.000.000.00206.349.770.00
Issuance or Reduction of Debt, Net0.0029.980.000.000.000.00
Change in Long Term Debt0.0029.980.000.000.000.00
Issuance of Long Term Debt0.0029.980.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.410.000.690.580.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities6.1832.341.70216.6811.590.89
Net Change in Cash-8.699.76-2.23-49.5213.334.66
Free Cash Flow-40.20-44.20-62.24-43.32-47.83-47.95

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3024.38%6.9M28.2M807.33K
2026-10-1526.49%7.5M28.2M489.13K
2026-09-3025.83%7.3M28.2M481.42K
2026-09-1525.60%7.2M28.2M548.28K
2026-08-3126.17%7.4M28.1M530.02K
2026-08-1425.90%7.3M28.4M532.49K
2026-07-3126.78%7.4M27.6M566.12K
2026-07-1526.54%7.3M27.5M569.36K
2026-06-3023.16%6.4M27.5M526.87K
2026-06-1521.78%6.0M27.6M462.97K
2026-05-2921.70%6.0M27.7M488.52K
2026-05-1520.78%5.7M27.3M592.93K
2026-04-3019.12%5.5M29.0M649.68K
2026-04-1518.11%5.2M28.9M674.49K
2026-03-3118.95%5.5M28.8M698.58K
2026-03-1315.60%4.5M28.8M740.85K
2026-02-2714.82%4.3M28.8M710.69K
2026-02-1311.97%3.4M28.5M648.54K
2026-01-3015.14%4.1M27.1M570.84K
2026-01-1515.81%4.3M27.1M621.13K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call25.0060.0064.5036.486.9351.000.000.997-0.0270.001
call30.0055.0059.5041.105.9951.000.000.996-0.0270.002
call35.0050.0054.500.004.9790.000.000.996-0.0280.002
call40.0045.0049.5036.824.3491.000.000.995-0.0280.002
call45.0040.0044.5021.063.7991.000.000.994-0.0280.002
call50.0035.0039.5027.303.3086.000.000.993-0.0280.003
call55.0030.0034.5015.202.86267.000.000.992-0.0280.003
call60.0025.0029.5018.802.4523,0840.000.990-0.0280.004
call65.0020.0024.5012.122.06871.000.000.980-0.0420.007
call70.0015.0019.509.001.7023,1270.000.940-0.0940.016
call75.0010.1013.2012.500.9785461.000.846-0.1930.032
call80.005.5010.008.001.1064707.000.785-0.1760.040
call85.003.506.504.001.0032033.000.595-0.2950.052
call90.001.504.001.540.6925,8012580.414-0.2260.053
call95.000.052.800.050.9961181.000.317-0.2750.048
call1000.352.250.501.1811,8311.000.256-0.2930.044
call1050.004.900.151.4296800.000.218-0.3200.039
call1100.001.400.561.3551,0482570.159-0.2530.033
call1150.004.900.001.5200.000.000.146-0.2680.031
call1200.004.900.131.69611.000.000.135-0.2820.029
put25.000.000.050.033.0252,2390.00-0.003-0.0220.001
put30.000.000.050.042.5922,3630.00-0.004-0.0210.002
put35.000.000.050.032.2997310.00-0.005-0.0230.002
put40.000.004.900.051.9852990.00-0.005-0.0220.002
put45.000.000.050.051.6359010.00-0.006-0.0200.002
put50.000.000.450.051.5244440.00-0.007-0.0220.003
put55.000.000.050.101.1572,3570.00-0.009-0.0190.003
put60.000.000.050.101.8245,6390.00-0.096-0.2190.024
put65.000.000.100.160.9662070.00-0.028-0.0470.009
put70.000.000.350.050.9501,0541.00-0.060-0.0860.016
put75.000.002.000.051.0274404.00-0.154-0.1850.032
put80.000.005.001.250.72211812.00-0.215-0.1670.040
put85.001.004.102.850.95813.000.00-0.405-0.2850.052
put90.003.006.2011.330.8475.000.00-0.586-0.2160.053
put95.007.0010.500.001.0220.000.00-0.683-0.2650.048
put10011.6015.0021.651.1641.000.00-0.744-0.2820.044
put10516.6020.000.001.3810.000.00-0.773-0.3130.041
put11021.4025.000.001.5760.000.00-0.841-0.2410.033
put11526.7030.000.001.7530.000.00-0.854-0.2550.031
put12031.2035.000.001.9180.000.00-0.864-0.2680.030

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-05424B5SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-26SCHEDULE 13D/ASEC
2026-10-228-KCurrent report2026-10-19SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-214Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-21424B5SEC
2026-10-20144Filing for proposed sale of securities under Rule 144.SEC
2026-10-20144Filing for proposed sale of securities under Rule 144.SEC
2026-10-20144Filing for proposed sale of securities under Rule 144.SEC
2026-10-20144Filing for proposed sale of securities under Rule 144.SEC
2026-10-20424B5SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-19144Filing for proposed sale of securities under Rule 144.SEC
2026-10-198-KCurrent report2026-10-19SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-11144Filing for proposed sale of securities under Rule 144.SEC
2026-09-108-KCurrent report2026-09-09SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10003.35M3
2026-09006.41M5
2026-08003.83M5
2026-07002.48M2
2026-06005.12M7
2026-050000
2026-0400841.28K3
2026-0300486.07K1
2026-02002.51M8
2026-0100581.21K2
2025-120021.84M7
2025-11002.54M1

Institutional holders

Manager% owned
FMR LLC12.51%
BlackRock, Inc.6.46%
RA CAPITAL MANAGEMENT, L.P.6.41%
JPMORGAN CHASE & CO4.91%
PRICE T ROWE ASSOCIATES INC /MD/4.91%
WELLINGTON MANAGEMENT GROUP LLP4.56%
STATE STREET CORP4.32%
Vestal Point Capital, LP4.06%
Atlas Venture Life Science Advisors, LLC3.60%
VANGUARD CAPITAL MANAGEMENT LLC3.58%

Funds

Fund% owned
Strategic Advisers Fidelity U.S. Total Stock Fund5.60%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.54%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.51%
iShares Russell 2000 ETF1.94%
JPMorgan Mid Cap Growth Fund1.70%
T. Rowe Price New Horizons Fund, Inc.1.48%
Select Biotechnology Portfolio1.18%
Eventide Healthcare & Life Sciences Fund1.03%
Select Health Care Portfolio0.99%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.98%

OakChart. IRON. Cached 15 minutes.